Beximco Pharmaceuticals Ltd.

New product launched in 2021

Beximco Pharmaceuticals Ltd. (BPL), a leading pharmaceutical in Bangladesh having global footprint across 55 countries with its prescription medicine & forefront in bringing new technology and generic products. New product and technology are the key growth drivers of Beximco pharma that launches a handsome number of products in Q1, 2021 across Cardiovascular, Gastrointestinal, Vitamins & Minerals and Ophthalmic portfolios.

Cardiovascular

Amdocal® Pro 2.5/5 Tablet

Bisoprolol Fumarate USP 2.5 mg and Amlodipine BP 5 mg

Amdocal® Pro consists of Amlodipine and Bisoprolol Fumarate. Bisoprolol Fumarate is a synthetic, beta1-selective (cardioselective) adrenoceptor blocking agent, lacking intrinsic sympathomimetic and relevant membrane stabilizing activity. Bisoprolol Fumarate is a synthetic, beta1-selective (cardioselective) adrenoceptor blocking agent, lacking intrinsic sympathomimetic and relevant membrane stabilizing activity.
Amdocal® Pro is indicated for the treatment of hypertension as substitution therapy in patients adequately controlled with the individual products given concurrently at the same dose level as in the combination, but as separate tablets.

Carnovas® HZ Tablet

Nebivolol INN 5 mg + Hydrochlorothiazide BP 12.5 mg

Nebivolol is a β adrenergic receptor blocking agent. Hydrochlorothiazide is a diuretic. It acts by increasing the amount of urine produced.
Carnovas® HZ is indicated for the treatment of raised blood pressure (hypertension). It is used instead of the two separate products for those patients who are already taking them together. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

Carnovas® Tablet

Nebivolol 2.5 mg, 5 mg & 10 mg

Nebivolol is a β adrenergic receptor blocking agent. Nebivolol inhibits both β1 and β2-adrenergic receptors.
Carnovas® indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Carnovas® is also indicated to Chronic Heart Failure (CHF): Treatment of stable mild and moderate chronic heart failure in addition to standard therapies in elderly patients 70 years old or above.

 

Vitamins & Minerals Supplement

D-Rise® 200000 IM Injection

Cholecalciferol BP 200000 IU

D-Rise® is a preparation of Cholecalciferol, a synthetic form of Vitamin D3. It is essential for normal bone growth and development and to maintain bone density. Cholecalciferol helps our body to utilize both Calcium and Phosphorus. It acts as a hormone and increases reabsorption of Calcium and Phosphorus by the kidneys.

Indication and Usage:
D-Rise® is indicated for the Treatment of Cholecalciferol deficiency states.

 

Eye Care

Odycin® D Eye Drops

Moxifloxacin 5 mg & Dexamethasone Phosphate 1 mg

Odycin® D is a combination of Moxifloxacin 0.5% and Dexamethasone Phosphate 0.1%. Odycin® D is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. The combination can also be used for post-operative inflammation and any other ocular inflammation associated with infection.

 

Gastrointestinal

Famomax® PFS

Famotidine USP 40 mg/5 ml

The active ingredient of Famomax® is Famotidine. Famotidine is a novel, highly specific and potent competitive H2- receptor antagonist. It has a rapid onset and prolonged duration of action. Famotidine reduces the acid and pepsin content, as well as the volume of basal, nocturnal and stimulated gastric secretion. Food or antacid does not interfere its absorption.
Famomax® Powder for Suspension is indicated in

  • Gastroesophageal reflux disease (GERD)
  • Dyspepsia
  • Peptic Ulcer